Tumor-Targeted Delivery of Curcumin via Hyaluronic Acid-Functionalized Polymeric Nanoparticles: Characterization and Mechanistic Insights into PI3K/AKT/mTOR Signaling
Aug 2026· BioNanoScience· Vol 16· 0 citations· 32 references
TL;DR
The promise of hyaluronic acid-based polymeric nanoparticles as a powerful nanoplatform to improve curcumin delivery and maximize anticancer effects by modulating key intracellular signaling pathways is highlighted, offering a strategy to overcome its biopharmaceutical limitations.
Lung cancer represents one of the most lethal malignancies worldwide, exhibiting both high incidence and mortality rates. It remains the primary cause of cancer-related deaths among men and women. Several factors contribute to its lethality including late diagnosis and the limited effectiveness of current treatme...
Lujain Alkhalaileh, M. Bayachou· Clinical Chemistry· 0 citations
A rational formulation strategy is suggested that supports improvements in curcumin's biopharmaceutical properties, offering further possibilities for pharmaceutical, nutraceutical, and cosmeceutical applications The systematic optimization approach provides a reproducible method for other poorly water-soluble bioactiv...
The clinical efficacy of vincristine (VIN) is often restricted by dose-limiting toxicity, poor tumor selectivity, and rapid systemic distribution. Another biomolecule, thymoquinone (TQ), has negligible toxicity, but poor aqueous solubility and limited bioavailability hamper its use in cancer therapy. In this study, a f...
S. Khan, Muhammad Rafiq, A. Raouf et al.· Colloids and Surfaces B: Bio...· 0 citations
Background: Trans-resveratrol (3,5,4′-trihydroxystilbene) is a natural polyphenolic antioxidant widely used in anti-aging dermocosmetics for its strong radical-scavenging capacity and its activation of cell-protective pathways such as sirtuin 1 (SIRT1). However, its poor aqueous solubility, photochemical lability, and...
Overall, nanotechnology can address important delivery barriers for quercetin and curcumin, but improved bioavailability should be treated as an enabling pharmacokinetic outcome rather than proof of therapeutic efficacy.
Rupali Patel, Poonam Dhote, Meenakshi Yadav et al.· Journal of Health Synapse· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.